What is BEAM's revenue growth forecast for 2024-2026?
(
NASDAQ
:
BEAM
)
Beam Therapeutics
's forecast annual revenue growth rate of
-44.84%
is
not
forecast to beat the
US
Biotechnology
industry's average forecast revenue growth rate of
34.56%
, and
while it is
not
forecast to beat the
US
market's average forecast revenue growth rate of
9.32%
.
Beam Therapeutics
's revenue in
2024
is
$352,567,000
.
On average, 7 Wall Street analysts forecast BEAM's revenue for 2024 to be $4,221,163,174, with the lowest BEAM revenue forecast at $2,406,536,075, and the highest BEAM revenue forecast at $6,181,171,425. On average, 6 Wall Street analysts forecast BEAM's revenue for 2025 to be $5,425,667,446, with the lowest BEAM revenue forecast at $1,648,312,380, and the highest BEAM revenue forecast at $8,241,561,900.
In 2026, BEAM is forecast to generate $4,334,402,234 in revenue, with the lowest revenue forecast at $30,493,779 and the highest revenue forecast at $9,065,718,090.